Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.75 USD
Change Today 0.00 / 0.00%
Volume 3.2K
SVON On Other Exchanges
As of 1:50 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

sevion therapeutics inc (SVON) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/29/14 - $1.79
52 Week Low
12/3/14 - $0.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sevion therapeutics inc (SVON) Related Businessweek News

No Related Businessweek News Found

sevion therapeutics inc (SVON) Details

Sevion Therapeutics, Inc., a biopharmaceutical company, engages in building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases. The company’s product candidates are derived from multiple proprietary technology platforms, including cell-based arrayed antibody discovery, ultralong antibody scaffolds, and Chimerasome nanocages. Its product pipeline includes VN-001, an ion channel blocking antibody against autoimmune disorders, including rheumatoid arthritis, psoriasis, and multiple sclerosis; SVN-002, an antibody against an oncology target; and SVN-003, a chimerasome/insulin product, which preferentially delivers insulin to the liver. The company was formerly known as Senesco Technologies, Inc. and changed its name to Sevion Therapeutics, Inc. in September 2014. Sevion Therapeutics, Inc. was founded in 1964 and is based in San Diego, California.

13 Employees
Last Reported Date: 09/29/14
Founded in 1964

sevion therapeutics inc (SVON) Top Compensated Officers

Scientific Founder
Total Annual Compensation: $67.5K
Chief Scientific Officer and Director
Total Annual Compensation: $23.1K
Compensation as of Fiscal Year 2014.

sevion therapeutics inc (SVON) Key Developments

Sevion Therapeutics, Inc. Provides Update on Immuno Oncology Discovery Program At Bio

provided an overview of the company's technology and programs by Dr. Miguel de los Rios, PhD, VP of Research and Development, at the BIO International Convention in Philadelphia, PA. The company has successfully completed an antibody discovery screening effort on both internal and partnered targets. The internal discovery program includes novel oncology GPCR targets. The company believed it has a position in the expanding field of immuno oncology, where several transmembrane proteins are currently not drugged due to discovery technology limitations. Additionally, the company has expanded and optimized production of its arrayed antibody library, which will enhance the efficiency by which it discovers leads for difficult transmembrane targets. SVN-001 Development. The company's humanized cow antibody targeting the ion channel Kv1.3 for autoimmune disease was engineered to have a unique dual mode of action, which has been confirmed in T-cell inhibitory assays. The potency of SVN-001 is in the subnanomolar range in vitro.

Sevion Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:30 AM

Sevion Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:30 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Miguel A. De Los Ríos, Vice President of Research and Development.

Sevion Therapeutics, Inc. Announces Executive Changes

Sevion Therapeutics, Inc. announced that on May 12, 2015, Joel Brooks delivered notice of his resignation as Chief Financial Officer, Secretary and Treasurer, effective May 15, 2015. The Board accepted Mr. Brooks’ notice of resignation. Mr. Schmidt will be appointed to the positions of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the company. Prior to Mr. Schmidt’s engagement by the company, he was providing independent financial consulting services to start-up and growing companies. He formerly served as the Vice President, Finance and Administration of Receptos, Inc. from 2009 to 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVON:US $0.75 USD 0.00

SVON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SVON.
View Industry Companies

Industry Analysis


Industry Average

Valuation SVON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 260.6x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 293.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEVION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at